99-25177. Viruses, Serums, Toxins, and Analogous Products; Definitions  

  • [Federal Register Volume 64, Number 187 (Tuesday, September 28, 1999)]
    [Proposed Rules]
    [Pages 52247-52248]
    From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
    [FR Doc No: 99-25177]
    
    
    ========================================================================
    Proposed Rules
                                                    Federal Register
    ________________________________________________________________________
    
    This section of the FEDERAL REGISTER contains notices to the public of 
    the proposed issuance of rules and regulations. The purpose of these 
    notices is to give interested persons an opportunity to participate in 
    the rule making prior to the adoption of the final rules.
    
    ========================================================================
    
    
    Federal Register / Vol. 64, No. 187 / Tuesday, September 28, 1999 / 
    Proposed Rules
    
    [[Page 52247]]
    
    
    =======================================================================
    -----------------------------------------------------------------------
    
    DEPARTMENT OF AGRICULTURE
    
    Animal and Plant Health Inspection Service
    
    9 CFR Part 101
    
    [Docket No. 99-040-1]
    
    
    Viruses, Serums, Toxins, and Analogous Products; Definitions
    
    AGENCY: Animal and Plant Health Inspection Service, USDA.
    
    ACTION: Proposed rule.
    
    -----------------------------------------------------------------------
    
    SUMMARY: We are proposing to amend the Virus-Serum-Toxin Act 
    regulations by adding a definition of the term dog to include all 
    members of the species Canis familiaris, Canis lupus, or any dog-wolf 
    cross. APHIS believes that dogs, wolves, and any dog-wolf cross can be 
    safely and effectively vaccinated with canine vaccines. This action 
    would allow canine vaccines that are recommended for use in dogs to be 
    recommended for use in wolves and any dog-wolf cross.
    
    DATES: We invite you to comment on this docket. We will consider all 
    comments that we receive by November 29, 1999.
    
    ADDRESSES: Please send your comment and three copies to: Docket No. 99-
    040-1, Regulatory Analysis and Development, PPD, APHIS, Suite 3C03, 
    4700 River Road, Unit 118, Riverdale, MD 20737-1238. Please state that 
    your comment refers to Docket No. 99-040-1.
        You may read any comments that we receive on this docket in our 
    reading room. The reading room is located in room 1141 of the USDA 
    South Building, 14th Street and Independence Avenue, SW., Washington, 
    DC. Normal reading room hours are 8 a.m. to 4:30 p.m., Monday through 
    Friday, except holidays. To be sure someone is there to help you, 
    please call (202) 690-2817 before coming.
        APHIS documents published in the Federal Register, and related 
    information, including the names of organizations and individuals who 
    have commented on APHIS rules, are available on the Internet at http://
    www.aphis.usda.gov/ppd/rad/webrepor.html.
    
    FOR FURTHER INFORMATION CONTACT: Dr. Albert P. Morgan, Chief Staff 
    Officer, Operational Support Section, Center for Veterinary Biologics, 
    Licensing and Policy Development, APHIS, 4700 River Road Unit 148, 
    Riverdale, MD 20737-1231; (301) 734-8245.
    
    SUPPLEMENTARY INFORMATION:
    
    Background
    
        The regulations in 9 CFR part 112 set forth packaging and labeling 
    requirements for veterinary biological products. The Animal and Plant 
    Health Inspection Service (APHIS) requires a product's label to 
    identify the animals for which the product has been demonstrated to be 
    effective and safe. Paragraph (b) of Sec. 113.209 requires a rabies 
    vaccine to be tested for immunogenicity in each species for which it 
    will be recommended. Therefore, rabies vaccines recommended for use in 
    dogs may be tested in any member of the species historically named 
    Canis familiaris and recommended for use in breeds of dog of the 
    species Canis familiaris.
        In 1993, the second edition of ``Mammal Species of the World, A 
    Taxonomic and Geographic Reference,'' stated that domestic dogs, 
    formerly identified as Canis familiaris, were a member of the species 
    Canis lupus, which is the grey wolf. This publication is widely 
    accepted as the standard for mammalian taxonomy. However, there is 
    disagreement within the expert community.
        In 1995, as a result of reclassifying dogs into the species Canis 
    lupus, owners of wolves and dog-wolf crosses petitioned APHIS to 
    recognize rabies vaccines approved for use in dogs as effective in 
    wolves and dog-wolf crosses. The petitioners pointed out that many 
    jurisdictions do not recognize the vaccination of wolves and dog-wolf 
    crosses against rabies. Therefore, if these animals are involved in an 
    incident in which rabies vaccination is an issue, they may be subject 
    to euthanasia.
        In April 1996, after consulting with taxonomists regarding the 
    petition, APHIS hosted a meeting in Riverdale, MD, to review the issues 
    of whether dogs and wolves were members of the same species Canis lupus 
    and whether rabies vaccines recommended for use in dogs should be 
    considered effective in wolves and any dog-wolf cross. Experts from the 
    disciplines of animal taxonomy, molecular genetics, veterinary 
    immunology, wildlife biology, and veterinary public health attended the 
    meeting. During the meeting, there was disagreement as to whether dogs 
    and wolves belonged to the same species, but there was consensus that 
    inactivated rabies vaccines should be safe and effective in wolves and 
    any dog-wolf cross. It was proposed that if rabies vaccines could be 
    assumed to be safe and effective in wolves and dog-wolf crosses, then 
    modified live vaccines against other dog diseases should also be safe 
    and effective in wolves and dog-wolf crosses. However, the experts 
    could not agree to this proposal without data demonstrating the safety 
    of modified live canine vaccines in wolves and dog-wolf crosses. 
    Without a clear consensus that the immune systems of wolves and dogs 
    were equivalent, APHIS took no action at that time to allow canine 
    vaccines that were recommended for use in dogs to be recommended for 
    use in wolves and any dog-wolf cross.
        As a follow up to the meeting, wolf and dog-wolf cross fanciers 
    submitted supplemental data to support the use of modified live canine 
    vaccines in wolves and dog-wolf crosses. The data indicated that 216 
    wolves and 460 dog-wolf crosses were vaccinated with various modified 
    live canine vaccines without any reported adverse reactions 
    attributable to the vaccines. Many of these animals received multiple 
    vaccinations over several years. These data provide only limited 
    statistical inference; however, the fact that wolves and dog-wolf 
    crosses share the same environment with dogs and have similar exposure 
    to disease agents with ample evidence of protection against those 
    diseases for which the animals were vaccinated provide strong evidence 
    that wolves and dog-wolf crosses respond to canine vaccines in a manner 
    similar to dogs. Further, the lack of reported adverse reactions after 
    vaccination provides strong epidemiological evidence that wolves and 
    dog-wolf crosses respond to canine vaccines in a manner similar to 
    dogs. In addition, manufacturers of canine vaccines acknowledge that 
    their products have
    
    [[Page 52248]]
    
    been used extensively in wolves and dog-wolf crosses with no reported 
    adverse reactions.
        Based upon the above, APHIS believes that dogs, wolves, and any 
    dog-wolf cross can be safely and effectively vaccinated with canine 
    vaccines. Therefore, we are proposing to add a definition of dog to 9 
    CFR part 101 to include all members of the species Canis familiaris, 
    Canis lupus, or any dog-wolf cross. This would allow canine vaccines 
    recommended for use in dogs to be recommended for use in wolves and any 
    dog-wolf cross. Manufacturers who wish to include wolves and dog-wolf 
    crosses on the labels for their canine vaccines could add these animals 
    to the labels. APHIS believes that, even without this change, all 
    canine vaccines labeled for use in dogs would be accepted as being safe 
    and effective in wolves and any dog-wolf cross. If manufacturers wish 
    to include wolves and any dog-wolf cross on their labels, the labels 
    would first need to be approved by and filed with APHIS.
        We would not require additional efficacy and safety studies to be 
    performed; however, manufacturers could perform additional efficacy and 
    safety studies, at their discretion, prior to recommending the use of 
    their canine vaccines in wolves and any dog-wolf cross.
    
    Executive Order 12866 and Regulatory Flexibility Act
    
        This rule has been reviewed under Executive Order 12866. The rule 
    has been determined to be not significant for the purposes of Executive 
    Order 12866 and, therefore, has not been reviewed by the Office of 
    Management and Budget.
        This proposed rule would amend the Virus-Serum-Toxin Act 
    regulations by adding a definition of the term dog to include all 
    members of the species Canis familiaris, Canis lupus, or any dog-wolf 
    cross. As a consequence, canine vaccines that are recommended for use 
    in dogs could also be recommended for use in wolves and any dog-wolf 
    cross. Manufacturers could include wolves and any dog-wolf cross on the 
    labels for their canine vaccines. The labels would need to be approved 
    by and filed with APHIS.
        This proposed rule would affect all licensed veterinary biologics 
    establishments that produce vaccines for use in dogs. Currently, there 
    are approximately 150 veterinary biologics establishments. According to 
    the standards of the Small Business Administration, most of these 
    establishments would be classified as small entities, and approximately 
    10 percent of these establishments currently produce vaccines for use 
    in dogs. Because the efficacy and safety of licensed canine vaccines 
    have already been demonstrated in accordance with the regulations, and 
    because this proposed rule does not require manufacturers to replace 
    labels for their products for use in wolves and any dog-wolf cross, any 
    additional costs manufacturers would incur if this proposed rule is 
    adopted should be minimal.
        Currently, manufacturers of veterinary biological products do not 
    recommend canine vaccines for use in wolves and any dog-wolf cross. 
    Under this proposed rule, if manufacturers recommend their canine 
    vaccines for use in wolves and dog-wolf crosses, additional efficacy 
    and safety data would not be required. Therefore, manufacturers would 
    not incur any additional costs as a result of the rule. This proposed 
    rule would not restrict manufacturers from using their discretion to 
    elect to perform additional efficacy and safety studies prior to 
    recommending the use of their canine vaccines in wolves and dog-wolf 
    crosses. However, if a canine vaccine is used on wolves or dog-wolf 
    crosses in accordance with the label recommendations, this proposed 
    rule would not relieve the manufacturer of responsibility for the 
    performance of the product (e.g., adverse reactions).
        Under these circumstances, the Administrator of the Animal and 
    Plant Health Inspection Service has determined that this action would 
    not have a significant impact on a substantial number of small 
    entities.
    
    Executive Order 12372
    
        This program/activity is listed in the Catalog of Federal Domestic 
    Assistance under No. 10.025 and is subject to Executive Order 12372, 
    which requires intergovernmental consultation with State and local 
    officials. (See 7 CFR part 3015, subpart V.)
    
    Executive Order 12988
    
        This proposed rule has been reviewed under Executive Order 12988, 
    Civil Justice Reform. It is not intended to have retroactive effect. 
    This rule would not preempt any State or local laws, regulations, or 
    policies, unless they present an irreconcilable conflict with this 
    rule. The Act does not provide administrative procedures which must be 
    exhausted prior to a judicial challenge to the provisions of this rule.
    
    Paperwork Reduction Act
    
        This proposed rule contains no information collection or 
    recordkeeping requirements under the Paperwork Reduction Act of 1995 
    (44 U.S.C. 3501 et seq.).
    
    Regulatory Reform
    
        This action is part of the President's Regulatory Reform 
    Initiative, which, among other things, directs agencies to remove 
    obsolete and unnecessary regulations and to find less burdensome ways 
    to achieve regulatory goals.
    
    List of Subjects in 9 CFR Part 101
    
        Animal biologics.
    
        Accordingly, we propose to amend 9 CFR part 101 as follows:
    
    PART 101--DEFINITIONS
    
        1. The authority citation for part 101 would continue to read as 
    follows:
    
        Authority: 21 U.S.C. 151-159; 7 CFR 2.22, 2.80, and 371.2(d).
    
        2. In Sec. 101.2, a definition of ``dog'' would be added in 
    alphabetical order to read as follows:
    
    
    Sec. 101.2  Administrative terminology.
    
    * * * * *
        Dog. All members of the species Canis familiaris, Canis lupus, or 
    any dog-wolf cross.
    * * * * *
    Done in Washington, DC, this 22nd day of September 1999.
    Bobby R. Acord,
    Acting Administrator, Animal and Plant Health Inspection Service.
    [FR Doc. 99-25177 Filed 9-27-99; 8:45 am]
    BILLING CODE 3410-34-U
    
    
    

Document Information

Published:
09/28/1999
Department:
Animal and Plant Health Inspection Service
Entry Type:
Proposed Rule
Action:
Proposed rule.
Document Number:
99-25177
Dates:
We invite you to comment on this docket. We will consider all comments that we receive by November 29, 1999.
Pages:
52247-52248 (2 pages)
Docket Numbers:
Docket No. 99-040-1
PDF File:
99-25177.pdf
CFR: (1)
9 CFR 101.2